Put companies on watchlist
Akero Therapeutics
ISIN: US00973Y1082
WKN: A2PLNP
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Akero Therapeutics · ISIN: US00973Y1082 · PR Newswire (ID: 20240823DC90227)
23 August 2024 05:46PM

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)


NEW YORK, Aug. 23, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Akero Therapeutics, Inc. (NASDAQ: AKRO) on behalf of the company's shareholders. The investigation seeks to determine whether Akero's directors breached their fiduciary duties in connection with recent corporate actions.

If you are a shareholder of Akero Therapeutics, Inc. and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us at: https://pjlfirm.com/akero-therapeutics-inc/

You may also contact Robert H. Lefkowitz, Esq. either via email at rl@pjlfirm.com or by telephone at 212-725-1000. One of our attorneys will personally speak with you about the case at no cost or obligation.

Purcell & Lefkowitz LLP is a law firm exclusively committed to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty and other types of corporate misconduct. For more information about the firm and its attorneys, please visit https://pjlfirm.com. Attorney advertising. Prior results do not guarantee a similar outcome.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-purcell--lefkowitz-llp-announces-shareholder-investigation-of-akero-therapeutics-inc-nasdaq-akro-302229508.html

SOURCE Purcell & Lefkowitz LLP

Visual performance / price development - Akero Therapeutics
Smart analysis and research tools can be found here.
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2025
PR Newswire
Contact:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942